目的 探讨血浆D-二聚体在晚期非小细胞肺癌(NSCLC)化疗疗效评价中的意义.方法 选取2014年1月至2017年9月晚期初治非小细胞肺癌患者86例,均采用多西他赛联合顺铂方案化疗≥2个周期,化疗前后测定血浆D-二聚体水平,分析D-二聚体水平与化疗疗效的相关性.结果 部分缓解的患者化疗后D-二聚体水平较化疗前明显下降(P<0.05),疾病稳定组D-二聚体水平化疗前后无明显变化,疾病进展的患者化疗后D-二聚体水平较化疗前显著上升,差异有统计学意义(P<0.05);化疗前Ⅳ期的NSCLC患者血浆D-二聚体水平较Ⅲ期NSCLC患者明显升高(P<0.05),D-二聚体水平在肺腺癌患者中较肺鳞癌患者显著升高,差异有统计学意义(P<0.05).结论 观察组化疗前后晚期NSCLC血浆D-二聚体水平对于评估病情、化疗疗效的预判具有一定价值.%Objective To investigate the significance of plasma D-dimer in evaluating the therapeutic efficacy of advanced non-small cell lung cancer(NSCLC)with chemotherapy. Methods 86 cases of patients with advanced NSCLC admitted to our oncology department from January 2014 to September 2017 were enrolled in our study. All patients were treated at least 2 cycles of chemotherapy with Docetaxel combined with Cisplatin. The levels of plasma D-dimer were measured before and after chemotherapy. The correlations between the D-dimer and the efficacy of chemotherapy were analyzed retrospectively. Results The levels of plasma D-dimer declined significantly after chemotherapy in the partial response(PR)group,P<0.05, but showed no significantly change in the stable disease(SD)group. However in the progressive disease(PD)group,the plasma D-dimer increased significantly after chemotherapy,P<0.05. Before chemotherapy,the D-dimer levels in stage Ⅳ patients were significantly higher than those in stage Ⅲ, P<0.05,and the D-dimer levels in patients with adenocarcinoma were higher than patients with squamous-cell carcinoma,P<0.05. Conclusion The plasma D-dimer maybe helpful to evaluate chemotherapy response and stage of disease in patients with advanced NSCLC during chemotherapy.
展开▼
